Literature DB >> 23683743

Sarcoidosis associated with neuromyelitis optica.

Raja Sawaya1, Wael Radwan.   

Abstract

Neuromyelitis optica (NMO) is an autoimmune disorder diagnosed by an elongated spinal cord lesion associated with unilateral or bilateral optic neuritis and anti-aquaporin 4 (AQP4) antibodies in the serum. It is triggered by or associated with several autoimmune diseases, but not with sarcoidosis. It responds to immunomodulators better than to steroid treatment. Sarcoidosis is an autoimmune disorder which manifests as non-caseating granulomas, usually in the lung parenchyma, but also in other tissues, including the brain. The involvement of the central nervous system in neurosarcoidosis differs considerably from that in neuromyelitis optica and the association of these two diseases concurrently in the same patient is unusual.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-aquaporin 4; Autoimmune diseases; Neuromyelitis optica; Rituximab; Sarcoidosis

Mesh:

Year:  2013        PMID: 23683743     DOI: 10.1016/j.jocn.2012.09.030

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  9 in total

Review 1.  Neuromyelitis optica spectrum disorders associated with other autoimmune diseases.

Authors:  Eduardo Freitas; Joana Guimarães
Journal:  Rheumatol Int       Date:  2014-06-22       Impact factor: 2.631

2.  A Case of Late-Onset Neuromyelitis Optica Spectrum Disorder Associated With Cryptogenic Organizing Pneumonia.

Authors:  Seung Won Ra; Soyeoun Lim; Hee Jeong Cha; Sunyoung Kim
Journal:  Clin Med Insights Case Rep       Date:  2022-05-18

Review 3.  Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis.

Authors:  Nadja Borisow; Masahiro Mori; Satoshi Kuwabara; Michael Scheel; Friedemann Paul
Journal:  Front Neurol       Date:  2018-10-23       Impact factor: 4.003

Review 4.  Refractory Sarcoidosis: A Review.

Authors:  Thomas El Jammal; Yvan Jamilloux; Mathieu Gerfaud-Valentin; Dominique Valeyre; Pascal Sève
Journal:  Ther Clin Risk Manag       Date:  2020-04-17       Impact factor: 2.423

Review 5.  Emerging Molecular Targets for the Treatment of Refractory Sarcoidosis.

Authors:  Gonçalo Boleto; Matheus Vieira; Anne Claire Desbois; David Saadoun; Patrice Cacoub
Journal:  Front Med (Lausanne)       Date:  2020-11-24

6.  Sarcoidosis and neuromyelitis optica in a patient with optic neuritis - a case report.

Authors:  Michael A Foster; Sara Collorone; Jacqueline Palace; James Acheson; Ahmed T Toosy
Journal:  Ann Clin Transl Neurol       Date:  2021-06-24       Impact factor: 5.430

7.  Rituximab in refractory sarcoidosis: a single centre experience.

Authors:  Francesco Cinetto; Nicolò Compagno; Riccardo Scarpa; Giacomo Malipiero; Carlo Agostini
Journal:  Clin Mol Allergy       Date:  2015-09-01

8.  Multisystem involvement in neuromyelitis optica.

Authors:  Megan M Langille; Jay Desai
Journal:  Ann Indian Acad Neurol       Date:  2015-09       Impact factor: 1.383

9.  Successful therapy with rituximab in three patients with probable neurosarcoidosis.

Authors:  Samis Zella; Janina Kneiphof; Aiden Haghikia; Ralf Gold; Dirk Woitalla; Jan Thöne
Journal:  Ther Adv Neurol Disord       Date:  2018-10-26       Impact factor: 6.570

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.